BiotechDueDiligence and HSP90 Central will be covering the 2013 AACR Annual Meeting live from Washington DC. This post will focus on abstracts to be presented by Astex Pharmaceuticals ASTX (partnered pipeline - see Parts 1 and 3 for internal ASTX assets), ArQule Inc ARQL, and BioSante Pharma BPAX.
Full coverage:
Introduction
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Full coverage:
Introduction
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Abstract numbers link you to fulltext c/o AACR.
Continuing coverage of Astex Pharmaceuticals ASTX presentations at #AACR 2013:
CDK4/CDK6 inhibition is potently active in a definable subset of human neuroblastomas Rader et al (Abstract 2744)
Focused on LEE011, partnered with Novartis - click here for more on this CDK4/6 inhibitor.
Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors - Banerji et al (Abstract LB-66)
Late-breaker, so no data available yet - stay tuned until April 5th. Partnered with AstraZeneca.
Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363 - Yates et al (Abstract 3352)
Generation of an acquired resistance model to the novel AKT inhibitor CCT129254 - Akan et al (Abstract 4447)
This is a precursor of AZD5363.
The molecular kinetics of p21 and Cdk4 dictates irreversible G0/G1 phase cell cycle arrest in CRPC cells - Gulappa et al (Abstract 559)
Studies with AT7519, in clinical development for multiple myeloma.
Continuing coverage of Astex Pharmaceuticals ASTX presentations at #AACR 2013:
CDK4/CDK6 inhibition is potently active in a definable subset of human neuroblastomas Rader et al (Abstract 2744)
Focused on LEE011, partnered with Novartis - click here for more on this CDK4/6 inhibitor.
Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors - Banerji et al (Abstract LB-66)
Late-breaker, so no data available yet - stay tuned until April 5th. Partnered with AstraZeneca.
Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363 - Yates et al (Abstract 3352)
Generation of an acquired resistance model to the novel AKT inhibitor CCT129254 - Akan et al (Abstract 4447)
This is a precursor of AZD5363.
The molecular kinetics of p21 and Cdk4 dictates irreversible G0/G1 phase cell cycle arrest in CRPC cells - Gulappa et al (Abstract 559)
Studies with AT7519, in clinical development for multiple myeloma.
Presentation from ArQule, Inc ARQL:
First-in-human study with ARQ 092, a novel pan AKT-inhibitor: Results from the advanced solid tumors cohorts - Saleh et al (LB-197)
This is the drug that, having seen this data, partner Daiichi-Sankyo just returned to ARQL. No fulltext available yet.
Presentation from Aveo Oncology AVEO:
AV-203, a fully humanized ERBB3 inhibitory antibody, reverses ERBB3-induced resistance to targeted therapies - Tyler et al (Abstract 1228)
Presentations from BioSante Pharma BPAX:
Pre-existing NY-ESO-1-specific T cell reactivity is associated with improved clinical outcome in castration resistant prostate cancer patients treated with Prostate GVAX and ipilimumab - Stam et al (Abstract 1229)
Inflammatory responses with infiltrating DC and functional cytotoxic T lymphocytes in the dermal vaccination sites of GVAX/ipilimumab treated prostate cancer patients - Santegoets et al (Abstract 496)
Two more presentations from this phase 1/2 GVAX+Yervoy trial from years ago has to have been presented at least a dozen times by now!
PD-1 blockade combined with TEGVAX (TLR agonists-enhanced GVAX) can induce regression of established palpable tumors - Malm et al (Abstract 3976)
First-in-human study with ARQ 092, a novel pan AKT-inhibitor: Results from the advanced solid tumors cohorts - Saleh et al (LB-197)
This is the drug that, having seen this data, partner Daiichi-Sankyo just returned to ARQL. No fulltext available yet.
Presentation from Aveo Oncology AVEO:
AV-203, a fully humanized ERBB3 inhibitory antibody, reverses ERBB3-induced resistance to targeted therapies - Tyler et al (Abstract 1228)
Presentations from BioSante Pharma BPAX:
Pre-existing NY-ESO-1-specific T cell reactivity is associated with improved clinical outcome in castration resistant prostate cancer patients treated with Prostate GVAX and ipilimumab - Stam et al (Abstract 1229)
Inflammatory responses with infiltrating DC and functional cytotoxic T lymphocytes in the dermal vaccination sites of GVAX/ipilimumab treated prostate cancer patients - Santegoets et al (Abstract 496)
Two more presentations from this phase 1/2 GVAX+Yervoy trial from years ago has to have been presented at least a dozen times by now!
PD-1 blockade combined with TEGVAX (TLR agonists-enhanced GVAX) can induce regression of established palpable tumors - Malm et al (Abstract 3976)
RSS Feed
